Chief Executive Officer and Co-Founder
Dr. Siciliano co-founded Invisible Sentinel in 2006 and was the lead inventor of the Company’s Veriflow technology. In his role as CEO, he sets corporate strategy, including sales and marketing initiatives and the identification of strategic partnerships. He also leads the R&D team, drawing on his more than 15 years of experience in microbiology, immunology, and assay development. He earned a B.S. in Chemistry from Villanova University and a Ph.D. in Immunology & Microbial Pathogenesis from Thomas Jefferson University. Formerly, Nick was a biomedical researcher in bacterial and viral pathogenesis, immunology, microbiology, and oncology, as well as a developer of antibody-based assays and consultant on projects in bacteriology, immunology, and antibody design. He has received several awards including Honoree on the annual “40 under 40” list compiled by the Philadelphia Business Journal to recognize outstanding entrepreneurs and business leaders. He was also a recipient of the 2015 Marcum/Smart CEO Innovator of the Year.
Chief Business Officer and Co-Founder
Mr. Pascal co-founded Invisible Sentinel in 2006. In his role as Chief Business Officer, he focuses on marketing and business development. He also works closely with the Sales function of the Company, helping to define sales strategies, identifying potential clients, supporting system implementation at key corporate accounts, and opening new international markets for the Company. Formerly he was a product developer at B. Braun Medical and the National Institute for Medical Research (London). Ben is an inventor on a corresponding patent to an antibacterial device and team member in the design of a functional cellular vaccine against malaria. He received a BS degree from The George Washington University in Biology and Political Science and an MBA from Lehigh University.
Dennis P Reilly
Chief Financial Officer
Mr. Reilly joined Invisible Sentinel in early 2017. He directs finance, human resources, manufacturing and operations for Invisible Sentinel. He has held various finance and operating roles over his professional career. For that past 15 years he has held executive positions in the life-sciences industries most recently at NeoStrata Company as Chief Financial Officer. Prior to NeoStrata, Dennis was VP of Finance and Chief Accounting Officer at Barrier Therapeutics, Director of Finance at The Medicines Company and held various finance and operational roles at Mobil Oil Corporation. He is a licensed CPA in Pennsylvania and hold a BS in Accounting from Villanova University and a MBA in Finance from Virginia Tech.
Mr. Touhey works closely with executive management at Invisible Sentinel to guide the strategic direction of the company. He brings to Invisible Sentinel more than 25 years of executive experience in the life-sciences and diagnostics industries and a record of fostering corporate success throughout his career. As the Chief Executive Officer of Fujirebio Diagnostics, he led that company to become an industry leader in cancer diagnostics. He was also a member of the Board of Directors of Fujirebio Diagnostics and its corporate parent, Fujirebio Inc. Prior to that role, Paul was Vice President of Operations in the Diagnostics Division of Centocor, Inc. He is currently a member of the Board of Directors of the University City Science Center and, previously, of Orthovita, Inc., a biomaterials company, and Cernostics, Inc., a molecular-cancer-diagnostics company. Paul is the recipient of both the Leadership Award and the CEO of the Year Award from Pennsylvania BIO.
Mr. Peacock is a venture partner at SV Life Sciences Advisors and has more than 30 years of executive experience in the life-sciences industry. He was former Chief Financial and Business Officer of Opthotech, Inc., a developer of biopharmaceuticals for eye diseases. Prior to that he served as Chief Operating Officer of Cephalon, Inc. and he lead the organization in the successful launch of Provigil®, Cephalon’s first and proprietary pharmaceutical product. Mr. Peacock was the Chief Executive Officer of Orthovita Inc. and Adolor Corp. He was also the Chief Financial Officer of Centocor, Inc. and was instrumental in raising over $850 million through debt and equity issues and corporate alliances.
Vice President, Operations
Mr. Courtney directs manufacturing for the complete line of Veriflow test kits at Invisible Sentinel’s production facility at the University City Science Center in Philadelphia. He is responsible for Good Manufacturing Practices (GMP) and efficient delivery required to ensure that every Invisible Sentinel customer will benefit from the inherent advantages of Veriflow® technology. Prior to joining Invisible Sentinel, Patrick was the director of process-improvement and quality-assurance programs in various companies, including Medco Health Solutions, Fresenius Medical Care, and Centocor, Inc., and he is a Six Sigma Master Black Belt.
Head of Sales
Mr. Lydon joined Invisible Sentinel in early 2016. As Head of Sales he is responsible for leading the revenue generating efforts of both the domestic and international sales groups, drawing on more than 15 years of sales leadership and diagnostic experience with IDEXX Labs and Alcon Pharmaceuticals. He has been recognized several times for exceptional team performance, including being named to President’s Club (top 10% of the organization) 5 times in his career. He earned a B.S. in Business Administration from the University of Richmond in Richmond, VA.